MRNA ▼ -5.3% - Moderna, Inc. $MRNA - Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines Moderna received U.S. FDA approval for its updated COVID-19 vaccines for the 2026-2027 season, yet shares fell 5.3% today. The decline suggests investors may be concerned about declining demand for COVID-19 vaccines as the pandemic recedes, or they were pricing in higher expectations for the approval announcement. The regulatory clearance itself represents a positive development for the company's vaccine pipeline, but market sentiment appears focused on longer-term revenue headwinds in this category. 27-AUG-2026 03:57 PM ET